Sign In
Buy BAYRY
$9.92
+0.0400 (+0.405%)
At Close: Jun 03, 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III ARANOTE trial, investigating NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cance
Bayer and Kroger Team Up with Luke Bryan and Feeding America to Improve Access to Nutritious Food
03:30pm, Saturday, 13'th Jul 2024
CINCINNATI--(BUSINESS WIRE)--Bayer and Kroger joined forces with country music star Luke Bryan and Feeding America to bring healthy food to more families who need it. According to Feeding America's la
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
03:01pm, Wednesday, 26'th Jun 2024
Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.
Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia
02:39pm, Wednesday, 26'th Jun 2024
A top Bayer pharmaceutical executive said on Wednesday his group will continue slashing managerial jobs this year, planning cuts in Germany, Japan, the United Kingdom, Belgium and the Netherlands as p
Bayer and Solynta Collaborate to Advance True Potato Seed in Smallholder Markets
07:16pm, Sunday, 23'rd Jun 2024
WAGENINGEN, Netherlands--(BUSINESS WIRE)--Bayer and Solynta have reached an agreement to collaborate on the commercialization and distribution of true potato seeds in Kenyan and Indian markets. This p
Bayer looks to AI to combat herbicide resistance faster
07:00pm, Tuesday, 18'th Jun 2024
Bayer's crop science division is increasingly turning to artificial intelligence in its battle against crop killing weeds, the company told Reuters.
Judge cuts Bayer $2.25 billion Roundup verdict to $400 million
06:50pm, Tuesday, 04'th Jun 2024
A Pennsylvania judge on Tuesday slashed a $2.25 billion U.S. verdict against Bayer to $400 million for a Pennsylvania man who said he developed cancer from exposure to the company's Roundup weedkiller
Bayer, maker of Roundup weedkiller, steps up fight against cancer-related lawsuits
09:41pm, Tuesday, 21'st May 2024
JEFFERSON CITY, Mo. — After failing in several U.S. states this year, global chemical manufacturer Bayer said Tuesday that it plans to amplify efforts to create a legal shield against a proliferatio
Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
09:18am, Wednesday, 15'th May 2024
BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of dosing in a Phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy. The inv
Bayer AG (BAYZF) Q1 2024 Earnings Call Transcript
12:53pm, Tuesday, 14'th May 2024
Bayer AG [BAYZF] Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Julio Triana - President, Consumer Health Division St
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
10:00am, Tuesday, 14'th May 2024
Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
Bayer's Q1 adjusted profit beats analyst consensus
01:49am, Tuesday, 14'th May 2024
Bayer on Tuesday reported a 1.3% decline in adjusted earnings in the first quarter, beating analysts' forecasts on better-than-expected performance at its prescription drugs and agriculture divisions.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present Kerendia® (finerenone) data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) i
WomenHeart and Bayer Join Forces to Enhance Heart Health Awareness and Education Among Women Across the U.S.
11:26am, Friday, 10'th May 2024
WASHINGTON--(BUSINESS WIRE)--WomenHeart: The National Coalition for Women with Heart Disease, in collaboration with Bayer, is proud to announce the launch of the Understanding Her Heart: Women and Car
BERLIN--(BUSINESS WIRE)--Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, evaluating the efficacy and safety of the investigational compound elinzanetant versus pl
